Glenmark Pharmaceuticals Limited has informed the Exchange regarding Cessation of Mr. V.S. Mani as Executive Director of the company w.e.f. May 26, 2025.
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.2 pts less than Nifty Midcap 150 and 0.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Glenmark Pharmaceuticals has informed the stock exchange about the cessation of Mr. V.S. Mani from the position of Executive Director, effective May 26, 2025. The announcement does not specify the reason for his departure. No details about a successor or restructuring of the board have been mentioned in this filing. Mr. Mani was part of the company's executive leadership as an Executive Director.
Investors should monitor for further disclosures regarding the reason behind Mr. V.S. Mani's exit and any succession plans. A single senior-level departure without clear context may create short-term uncertainty, but its impact on stock price depends on the role and influence he held within the company.